A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants
Event: ESC Congress 2022
Topic: Anticoagulants
Session: Challenges and advances in antithrombotic therapy
